

## Chiglitazar: Adis Evaluation

### Key Points

- Pan-PPAR agonist being developed by Chipscreen Biosciences for the treatment of T2D and non-alcoholic steatohepatitis
- Received its first approval on 19 October 2021 in China
- Approved for use as an adjunct to diet and exercise to improve glycaemic control in adult patients with T2D

### Summary

Chiglitazar (Bilessglu®) is an orally administered, non-thiazolidinedione small-molecule agonist of  $\alpha$ ,  $\delta$  and  $\gamma$  peroxisome proliferator-activated receptors (PPARs) being developed by Chipscreen Biosciences for the treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis.

In October 2021, chiglitazar was approved in China for use as an adjunct to diet and exercise to improve glycaemic control in adult patients with T2D. The drug is also in phase 2 clinical development in China for the treatment of non-alcoholic steatohepatitis.

This article summarizes the milestones in the development of chiglitazar leading to this first approval for the treatment of T2D.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2021.